Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026

Pivotal Phase 3 WU-KONG28 Study of ZEGFROVY® selected as Late-Breaking Abstract Oral presentation for DZD6008, the 4th generation EGFR TKI, in EGFR mutated NSCLC after Tagrisso and other 3rd generation EGFR TKI treatment Poster presentation on clinical benefits of golidocitinib in...